Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cardiomyocytes From Induced Pluripotent Stem Cells From Patients and Methods of Use Thereof

a technology of cardiomyocytes, which is applied in the field of patient-induced pluripotent stem cells of cardiomyocytes, can solve the problems of undermining the value of these methodologies for understanding the cellular and physiological processes of dcm, disrupting the normal alignment of cardiomyocytes, and affecting the function of patients, so as to reduce the beating rate, improve the function, and compromise the effect of contraction

Inactive Publication Date: 2017-03-02
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
View PDF0 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a method for treating two types of heart disease, DCM and HCM, by stimulating cardiomyocytes with a β-adrenergic agonist, such as norepinephrine, before, during, or after contacting them with a candidate agent. The response of the cardiomyocytes to the stress is measured using various methods such as calcium imaging and gene expression analysis. The results show that the treatment improves the function of the cardiomyocytes and reverses the disease-related changes in their behavior. The patent also mentions that genetic agents and other molecular targets can be tested to further understand the pathways involved in heart disease and suggest potential treatments. Overall, this patent provides a method to study and treat heart disease by manipulating cardiomyocyte function.

Problems solved by technology

In addition, the normal alignment of cardiomyocytes is disrupted, a phenomenon known as myocardial disarray.
The lack of complex intracellular interactions within cardiomyocytes for in vitro biochemical assays and species differences for mouse models undercut the value of these methodologies for understanding the cellular and physiological processes of DCM as well as for drug screening.
In addition, cardiac tissues from DCM patients are difficult to obtain and do not survive in long-term culture.
The explosion in numbers of potential new targets and chemical entities resulting from genomics and combinatorial chemistry approaches over the past few years has placed enormous pressure on screening programs.
The rewards for identification of a useful drug are enormous, but the percentages of hits from any screening program are generally very low.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cardiomyocytes From Induced Pluripotent Stem Cells From Patients and Methods of Use Thereof
  • Cardiomyocytes From Induced Pluripotent Stem Cells From Patients and Methods of Use Thereof
  • Cardiomyocytes From Induced Pluripotent Stem Cells From Patients and Methods of Use Thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0117]Dilated cardiomyopathy (DCM) is the most common cardiomyopathy, characterized by ventricular dilatation, systolic dysfunction, and progressive heart failure. DCM is the most common diagnosis leading to heart transplantation and places a considerable burden on healthcare worldwide. Here we generated cardiomyocytes (CMs) from iPSCs derived from patients of a DCM family carrying a point mutation (R173W) in the gene that encodes sarcomeric protein cardiac troponin T. Compared to the control healthy individuals in the same family cohort, DCM iPSC-CMs exhibited decreased calcium transient amplitude, decreased contractility, and abnormal sarcomeric α-actinin distribution. When stimulated with β-adrenergic agonist, DCM iPSC-CMs showed characteristics of failure such as reduced beating rates, compromised contraction, and significantly more cells with abnormal sarcomeric α-actinin distribution. β-adrenergic blocker treatment and over-expression of sarcoplasmic reticulum Ca2+ ATPase (Ser...

example 2

Cardiomyocytes from Patients with Hypertrophic Cardiomyopathy

[0147]Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease of the cardiac sarcomere, and is estimated to be the most prevalent hereditary heart condition in the world. Patients with HCM exhibit abnormal thickening of the left ventricular (LV) myocardium in the absence of increased hemodynamic burden and are at heightened risk for clinical complications such as progressive heart failure, arrhythmia, and sudden cardiac death (SCD). Molecular genetic studies from the past two decades have demonstrated that HCM is caused by mutations in genes encoding for proteins in the cardiac sarcomere. While identification of specific mutations has defined the genetic causes of HCM, the pathways by which sarcomeric mutations lead to myocyte hypertrophy and ventricular arrhythmia are not well understood. Efforts to elucidate the mechanisms underlying development of HCM have yielded conflicting results, paradoxically supporting...

example 3

Cardiomyocytes from Patients with Anthracycline Toxicity

[0187]Anthracycline-induced cardiotoxicity (and resistance to anthracycline-induced toxicity). Anthracyclines such as doxorubicin are frontline chemotherapeutic agents that are used to treat leukemias, Hodgkin's lymphoma, and solid tumors of the breast, bladder, stomach, lung, ovaries, thyroid, and muscle, among other organs. The primary side effect of anthracyclines is cardiotoxicity, which results in severe heart failure for many of the recipients receiving regimens utilizing this chemotherapeutic agent. Patient specific iPSC-cardiomyocytes (iPSC-CMs) were derived from individuals who are susceptible to anthracycline-induced cardiotoxicity as well as from individuals who are not susceptible to anthracycline-induced cardiotoxicity.

[0188]These cells are useful to detect and titrate cardiotoxic chemotherapeutic drugs, as well as identify genes responsible for susceptibility / resistance to anthracycline-induced cardiotoxicity. Age...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like.

Description

CROSS-REFERENCE[0001]This application claims benefit and is a Continuation of Application of Ser. No. 13 / 554,946 filed Jul. 20, 2012, which claims benefit of U.S. Provisional Patent Application No. 61 / 510,422, filed Jul. 21, 2011, which applications are incorporated herein by reference in their entirety.FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT[0002]This invention was made with Government support under contract HL099776 awarded by the National Institutes of Health. The Government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]A variety of cardiac disorders have an underlying genetic cause. For example, dilated cardiomyopathy (DCM) is a cardiac disease characterized by ventricular dilatation and systolic dysfunction. DCM is the most common cause of heart failure after coronary artery disease and hypertension, as well as the leading indication for heart transplantations. The cost for management of DCM in the US alone has been estimated at between $4 and $10 bi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N5/077G01N33/50
CPCC12N5/0657C12N2506/45C12N2510/00G01N33/5061G01N2800/324G01N2800/325C12N5/0696C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2506/1307G01N33/5073A61P9/00C12Q1/6883C12N2503/02C12Q2600/158C12Q2600/136
Inventor SUN, NINGLONGAKER, MICHAEL T.ROBBINS, ROBERT C.WU, JOSEPHLAN, FENGLEE, ANDREW STEPHENBURRIDGE, PAUL W.
Owner THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com